Clinical Trial Update: A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ABT-494 (upadacitinib) with methotrexate in RA patients who failed anti-TNF therapy completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ABT-494 (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2018-06-27